The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer

Cancer

Volumn 119, Issue 3, 2013, Pages 681-690

  Shilkrut, Mark ^a   Merrick, Gregory S ^b   McLaughlin, P William ^a   Stenmark, Matthew H ^a   Abu Isa, Eyad ^a   Vance, Sean M ^a   Sandler, Howard M ^c   Feng, Felix Y ^a   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

brachytherapy; hormone therapy; prostatic neoplasms; radiation; treatment outcome

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CENTER; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UNITED STATES;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CARCINOMA; CAUSE OF DEATH; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872908046     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27784     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290.
3. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2010; 26: 211-218.
4. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 25-33.
5. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373: 301-308.
6. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
7. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
8. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.
9. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR,. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116: 5226-5234.
10. Zhao KH, Hernandez DJ, Han M,., et al. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008; 72: 396-400.
11. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM,. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys. 2003; 57: 384-390.
12. Fang LC, Merrick GS, Butler WM, et al. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011; 81: 992-996.
13. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
14. Fine J, Gray R,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
15. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 1990-1996.
16. Jani AB, Hand CM, Lujan AE, et al. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim. 2004; 29: 42-48.
17. Eade TN, Hanlon AL, Horwitz EM,. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007; 68: 682-689.
18. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomized, phase 3 trial. Lancet. 2011; 378: 2104-2111.
19. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol. 2009; 181: 956-962.
20. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366: 572-578.
21. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27: 2924-2930.
22. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005; 23: 1192-1199.
23. Hoskin PJ, Rojas AM, Bowne PJ, Lowe GJ, Ostler PJ, Bryant L,. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012; 103: 217-222.
24. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA,. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate-specific antigen and nadir prostate-specific antigen with outcome as assessed by systematic biopsy and serum prostate-specific antigen. Cancer. 1997; 79: 328-336.
25. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN,. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 1352-1359.
26. Krauss D, Kestin L, Ye H, et al. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 80: 1064-1071.
27. Hamstra DA, Bae K, Pilepich MV, et al. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011; 81: 1293-1301.
28. Wattson DA, Chen MH, Moul JW, et al. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012; 82: e773-e779.
29. Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN,. The impact of brachytherapy on prostate cancer specific mortality for definitive radiation therapy of high-grade prostate cancer: a population based analysis. Int J Radiat Oncol Biol Phys. 2012; 83: 1154-1159.
30. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group Study 0019. Cancer. 2007; 109: 1506-1512.
31. University of British Columbia. National Clinical Trial 00175396. Androgen suppression combined with elective nodal and dose-escalated radiation therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00175396. Accessed May 1, 2012.